X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Product Name: Sitagliptin-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
ICRI Spring Convention
Not Confirmed
Contact SupplierDetails:
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist. It is under phase 2 clinical development in combination with sitagliptin, a DPP4 inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Lead Product(s): DA-1241,Sitagliptin Phosphate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DA-1241
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
Through the acquisition, Cosmos will gain the license and rights for DIABIT-IS X, a drug that contains the active substance sitagliptin and is used in the treatment of type-2 diabetes.
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Product Name: DIABIT-IS X
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cosmos Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 20, 2023
Details:
Zituvio (Sitagliptin) tablets A is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Product Name: Zituvio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
Sitagliptin, Pioglitazone & Metformin are combined for the treatment of diabetes. Metformin, coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome and the stability of Sitagliptin, make an effective solution for diabetes.
Lead Product(s): Sitagliptin Phosphate,Pioglitazone,Metformin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
GMRx4 is being developed to provide a synergistic effect from three best-in-class type 2 diabetes treatments – metformin, dapagliflozin and sitagliptin – and, in an ultra-low-dose, single pill formulation, aims to be a more effective, simpler and safer treatment regimen.
Lead Product(s): Metformin,Dapagliflozin,Sitagliptin Phosphate
Therapeutic Area: Endocrinology Product Name: GMRx4
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CUREator
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 20, 2022
Details:
Januvia (sitagliptin), a class of dipeptidyl peptidase (DPP4) inhibitors, is used with a proper diet and exercise program and possibly with other medications to control high blood sugar.
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Product Name: Januvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
Under a research and development agreement, Codexis and Merck leveraged Codexis’ CodeEvolver® enzyme engineering platform technology to design a novel, proprietary enzyme to serve as a biocatalyst in the sitagliptin manufacturing process.
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Product Name: Januvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 09, 2021
Details:
Zydus’ Sitagliptin base contains the active moiety sitagliptin in a different form than used in the branded reference product, Januvia (sitagliptin phosphate).
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Product Name: Januvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Prague Scientific offers services across different areas in development, regulatory & pharmacovigilance.
